

CAMB/IMM 609: Vaccines & Immune Therapy Fall 2021

Time: 3:30 PM – 5:30 PM

Location: The Wistar Institute

Grossman Auditorium / GoToMeeting

Instructors: David Weiner, Paul Offit, Stanley Plotkin, Emilio Emini

Class Coordinator: Jeneice Hubert

V-Virtual Lecture / **IP** – In Person Lecture

<u>Date</u>	<u>Title</u>	<u>Lecturer</u>
Sept 22	Welcome/Vaccine History	David Weiner – Wistar IP
	B Cells, Antibodies, & Humoral Immune Response	David Allman – PENN IP
Sept 23	Cure-HIV	Luis Montaner – Wistar IP
	HPV	Alain Luxembourg – Merck V
Sept 29	Adoptive Cell Therapy for Cancer	Marco Ruella – UPENN IP
Sept 30	Cellular Immune Responses	Michael Betts - PENN
Oct 6	Pneumococcal Conjugate	William Gruber – Pfizer V
Oct 7	Personalized Cancer Vaccines	Gerald Linette – UPENN
Oct 13	Rotavirus Vaccines	Paul Offit – CHOP V
Oct 20	SARS CoV2 Vaccine Program	Tonya Villafana – AstraZeneca IP
	Passive Immunization with Suvratoxumab To Prevent S. Aureus Ventilator Associated Pneumonias	Mark Esser – AstraZeneca IP

JENEICE HUBERT

Weiner Lab Coordinator

Assistant to: Dr. David B. Weiner

P (215) 898-0381 E jhubert@wistar.org

<u>Date</u>	<u>Title</u>	<u>Lecturer</u>
Oct 21	Vaccine Safety	Paul Offit – CHOP V
Oct 27	Regulatory Considerations for Preventative Vaccines	Doran Fink – FDA V
	Understanding Vaccine Safety After Licensure	Meghna Alimchandani – FDA V
Oct 28	Correlates of Protection by Vaccines	Stanley Plotkin – Emeritus V Professor of Pediatrics
	The Challenge of Successful Vaccines Development & Delivery	Emilio Emini – Bill & Melinda Gates V Medical Research Institution
Nov 3	Overview of the Advisory Committee on Immunization practices (ACIP) Example: Hepatitis A Disease and Vaccines	Michelle Goveia – Merck V
Nov 4	Progress Towards the Development of A Prophylactic Vaccine for HCMV	Amy Espeseth – Merck IP
	Developing a SARS CoV-2 Vaccine at Warp Speed	Paul Offit – CHOP V
Nov 10	Development of a COVID-19 Vaccine At Lightspeed	Kathrin Jansen – Pfizer V
Nov 11	Developing a heterologous prime-boost Ebola vaccine – challenges and opportunities	Ruxandra Draghia-Akli – Janssen IP
	The Enigma of Dengue Vaccine Development	Kevin Russell – Merck V

JENEICE HUBERT

Weiner Lab Coordinator

Assistant to: Dr. David B. Weiner

P (215) 898-0381 **E** jhubert@wistar.org

<u>Date</u>	<u>Title</u>	<u>Lecturer</u>
Nov 17	Vaccines for Infectious Diseases that Disproportionately Impact the Poor	Penny Heaton – Janssen V
	Developing vaccines against emerging infections outside of the usual regulatory framework	Gary Kobinger – PHA Canada V
Nov 18	Structure-based Vaccines	Daniel Kulp – Wistar IP
Dec 1	Meningococcal Vaccines	Lucy McNamara – CDC V
Dec 2	Course Summary and Final Exam Review	David Weiner – Wistar IP
Dec 8	Final Exams	TBD

Waiting for Lecture Dates:

Vaccine Development for Emerging Infectious Diseases: Are we addressing lessons learned from the Ebola outbreaks?	Swati Gupta - IAVI
TBD/ Immunotherapy for the treatment of HPV diseases: T cells as key players	Kimberly Kraynyak – Inovio
Development of nirsevimab, A Monoclonal Antibody for the Prevention of RSV Disease in all infants	Danillo Casimiro – Sanofi Pasteur

JENEICE HUBERT

Weiner Lab Coordinator
Assistant to: Dr. David B. Weiner
P (215) 898-0381 E jhubert@wistar.org